The Obesity Inflection Point for Employer Health Plans

EMPLOYER HEALTH STRATEGY

Evolving Clinical Definitions for Employer Health Plans Means HR Leaders Can’t Afford to Wait

Something fundamental is shifting in how medicine understands obesity and the implications for employer-sponsored health plans are more profound than most benefit leaders currently recognize. The conversation has moved well beyond whether GLP-1 medications should be covered. The real question emerging now is this: as the clinical definition of obesity is redrawn, how many more employees will qualify for treatment, and is your plan prepared for what comes next?

“The question is no longer whether obesity is a disease. It is whether employers are prepared for what a far broader definition of that disease will cost and enable.”

From Lifestyle Issue to Chronic Condition: A Paradigm Already in Motion

Employer demand for GLP-1 coverage has surged precisely because employees no longer view these therapies as optional wellness perks — they view them as medically necessary. According to the 2025 KFF Employer Health Benefits Survey, 19% of employers with more than 200 employees now cover prescription weight-loss medications. Yet only 34% of those employers have put utilization management programs or step therapy requirements in place to govern that coverage.

That gap between coverage and stewardship is a vulnerability. And with adoption expected to continue expanding across organizations of all sizes, the window for proactive planning is narrowing. Employers who approach GLP-1 coverage reactively, adding benefits in response to talent pressure without building the policy architecture to manage them, are likely to face compounding cost exposure in the years ahead.

The Definition of Obesity Is Being Rewritten

For decades, a BMI of 30 or above served as the primary clinical threshold for an obesity diagnosis. That threshold is now under serious scientific scrutiny. Researchers affiliated with The Lancet Diabetes & Endocrinology Commission have proposed a more nuanced diagnostic framework ,one that incorporates waist circumference, waist-to-height ratio, and the presence of obesity-related comorbidities such as hypertension, dyslipidemia, and other metabolic risk factors.

The proposed framework introduces a critical distinction between two categories:

Clinical Obesity: Characterized by measurable organ dysfunction, metabolic impairment, or reduced physical functioning attributable to excess adiposity. Under this definition, obesity is unambiguously a chronic disease requiring active treatment.

Preclinical Obesity: Identifies individuals who do not yet exhibit measurable dysfunction but carry meaningful risk of future metabolic complications and functional decline. This category essentially creates a new, treatment-eligible population — one that previously fell outside the scope of obesity-related care.

The Scale of the Shift: From 40% to 75%

Here is where benefit leaders should pause. Approximately 40% of U.S. adults currently meet the clinical threshold for obesity under BMI-based criteria. Under the broader diagnostic frameworks now being proposed, These incorporate metabolic health, body composition, and associated risk factors, and some researchers estimate that figure could rise above 75%.

That is not an incremental change. It is a potential doubling of the eligible population. For self-insured employers in particular, the downstream implications for GLP-1 utilization, specialist referrals, and chronic disease management spend are significant. Even if only a fraction of newly eligible employees seek treatment, the actuarial exposure is material.

“Some researchers estimate that under broader clinical criteria, more than 75% of U.S. adults could qualify for obesity-related interventions — nearly double the current BMI-based estimate of 40%.”

The Strategic Imperative for Employers

Forward-looking organizations are already recognizing that this is not a benefits management problem,it is a strategic workforce health problem. Three capabilities are becoming essential:

Robustutilizationmanagement. Prior authorization, step therapy, and outcomes-based criteria are foundational tools — not optional add-ons. Employers without these guardrails in place are effectively operating without a cost-control mechanism in one of the fastest-growing expense categories in their health plan.
Clinically informed coverage criteria.As diagnostic standards evolve, coverage policies anchored exclusively to BMI thresholds may become both clinically outdated and legally uncertain. Employers should work with their carriers, TPAs, and clinical advisors to develop criteria that reflect emerging evidence whileremaining administratively defensible.
Integrated population health strategy.GLP-1 coverage does not exist in isolation. Itintersects with diabetes management, cardiovascular risk, musculoskeletal health, and behavioral health programs. Employers who treat obesity coverage as a standalone benefit, rather than as part of a coordinated chronic disease strategy, are likely to see diminished clinical outcomes and sub-optimal return on investment.

The Time for Deliberate Action Is Now

The clinical redefinition of obesity is not a distant hypothetical — it is an active scientific conversation with concrete policy implications. Employers who engage with it now, thoughtfully and proactively, will be far better positioned to design benefit structures that are financially sustainable, clinically sound, and genuinely valuable to their workforce.

Those who wait for the landscape to fully settle before acting may find that the landscape has already settled around them — at a cost they were not prepared to absorb.